Piper Jaffray Reiterates Overweight on MAKO Surgical

Piper Jaffray is out with its report today on MAKO Surgical MAKO, reiterating Overweight. In its report, Piper Jaffray writes, "We continue to view MAKO's surgical robotic arm as one of the most compelling innovations in orthopaedics in recent years. We reiterate our Overweight rating on MAKO and view the stock as attractive at current levels." At the time of posting, shares of MAKO were trading pre-market at $33.00, up 1.23% from Tuesday's close.